VEGF localisation in diabetic retinopathy
Open Access
- 1 May 1998
- journal article
- research article
- Published by BMJ in British Journal of Ophthalmology
- Vol. 82 (5) , 561-568
- https://doi.org/10.1136/bjo.82.5.561
Abstract
AIM To determine the staining pattern of vascular endothelial growth factor (VEGF) at different stages of diabetic retinopathy (including post-laser photocoagulation) and to compare staining in excised fibrovascular and fibrocellular (non-diabetic) preretinal membranes. METHODS Immunohistochemical localisation of VEGF, using antibodies raised against VEGF165 and VEGF121,165,189, was carried out on specimens of normal human retina (n=15), diabetic retinas ((a) with no overt retinopathy (n=19), (b) with intraretinal vascular abnormalities but no proliferative retinopathy (n=6), (c) with active proliferative retinopathy (n=6), (d) with no residual proliferative retinopathy after photocoagulation therapy (n=15)), excised diabetic fibrovascular membranes (n=19), and non-diabetic fibrocellular membranes (n=7). The degree and pattern of immunostaining was recorded. RESULTS In general, VEGF was absent from the majority of normal retinas. VEGF staining was apparent in most diabetic tissues but the staining pattern was dependent on both the specificity of the antibody used and the category of tissue. Staining with the VEGF165 antibody was generally confined to endothelial cells and perivascular regions while the VEGF121,165,189antibody was also associated with extravascular components of the inner retina. Intensity of immunostaining of diabetic eyes was dependent on the severity of retinopathy being least in diabetics with no overt retinopathy and greatest in retinas with proliferative retinopathy. Interestingly, the intensity of immunostaining in diabetic retinas which had undergone laser surgery for proliferative retinopathy was reduced to basal levels. Moderate to intense immunostaining was observed in all fibrovascular and fibrocellular membranes examined. CONCLUSIONS This study supports a circumstantial role for VEGF in the pathogenesis of both the preclinical and proliferative stages of diabetic retinopathy.Keywords
This publication has 29 references indexed in Scilit:
- Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cellsPublished by Elsevier ,2004
- Localisation of vascular endothelial growth factor and its receptors to cells of vascular and avascular epiretinal membranesBritish Journal of Ophthalmology, 1997
- Vascularised vitreoretinopathy: The role of growth factorsEye, 1996
- Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy.British Journal of Ophthalmology, 1996
- Vasculotropin/Vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultued in vitroJournal of Cellular Physiology, 1995
- Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide.Journal of Clinical Investigation, 1995
- Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal DisordersNew England Journal of Medicine, 1994
- The fms -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth FactorScience, 1992
- Vascular Endothelial Growth Factor Is a Secreted Angiogenic MitogenScience, 1989
- Tumors: Wounds That Do Not HealNew England Journal of Medicine, 1986